guanabenz has been researched along with Stargardt Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Dong, Z; Golczak, M; Maeda, A; Maeda, T; Mustafi, D; Palczewska, G; Palczewski, K; Sawada, O | 1 |
1 other study(ies) available for guanabenz and Stargardt Disease
| Article | Year |
|---|---|
Systems pharmacology identifies drug targets for Stargardt disease-associated retinal degeneration.
Topics: Adenine; Adenylyl Cyclase Inhibitors; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Alcohol Oxidoreductases; Animals; ATP-Binding Cassette Transporters; Cell Survival; Disease Models, Animal; Doxazosin; Drug Evaluation, Preclinical; Guanabenz; Humans; Light; Macaca fascicularis; Macular Degeneration; Mice; Mice, Inbred BALB C; Mice, Knockout; Molecular Targeted Therapy; Nerve Tissue Proteins; Photoreceptor Cells, Vertebrate; Reactive Oxygen Species; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-2; Receptors, G-Protein-Coupled; Serotonin Antagonists; Signal Transduction; Stargardt Disease | 2013 |